We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > CT-P13

News List

Celltrion secures EC approval for Remsima SC for five more indications pharmaceutical-business-review
July 29, 2020
Celltrion Healthcare has secured approval from the European Commission (EC) for the subcutaneous (SC) formulation of autoimmune disease drug Remsima (infliximab, CT-P13) for the treatment of five more indications.
Celltrion's infliximab biosimilar to be tested for COVID-19 pharmatimes
June 17, 2020
Celltrion Healthcare has partnered with the University of Oxford and University Hospitals Birmingham to investigate the use of infliximab biosimilar CT-P13 as a treatment for COVID-19 symptoms.
Celltrion Healthcare & Pfizer’s biosimilar shows positive results in Crohn’s disease study europeanpharmaceuticalreview
May 08, 2019
Celltrion Healthcare presented the primary outcome from its pivotal randomised controlled trial of CT-P13 (biosimilar infliximab) in Crohn’s disease.